Contributions
Abstract: PB1722
Type: Publication Only
Background
Acute myeloid leukemia (AML) is one of the common types of hematological malignancies in elderly people. Thus, how to select patients who are suitable to receive intensive induction chemotherapy is critical to improve the clinical outcomes of elderly patients with AML. Over the last few decades, geriatricians have developed comprehensive geriatric assessment (CGA) methods for elderly patients, which are useful for the evaluation of cancer patients. however, the tools used for CGA varied and not uniform in AML.
Aims
We aimed to validate the instrumental activities of daily living (IADL) scales, age, comorbidities, and albumin (IACA) index in elderly patients with acute myeloid leukemia (AML) and identify whether this index can serve as a guide for optimal personalized therapy for elderly patients with AML.
Methods
Patients aged ≥60 years, who had been diagnosed with AML in the Department of Hematology, Beijing Hospital, were screened for eligibility (n = 61).
Results
A total of 21, 34, and 6 patients were categorized as IACA low-risk, intermediate-risk, and high-risk groups, respectively. Thirty-nine patients received induction chemotherapy (IC, n=35) or decitabine (n=4) after diagnosis, 19 (48.7%) achieved complete remission (CR), and the rate of CR was significantly higher in the IACA low-risk group than that of intermediate-risk group (68.4% vs. 30.0%, P=0.016).The rates of grade ≥ 3 toxicities and treatment-related mortality were comparable between low- and intermediate-risk groups. The rate of relapse/progression-related mortality was 23.8%, 58.8%, and 100.0% in the IACA low-, intermediate-, and high-risk groups, respectively (P<0.001). The 2-year probability of overall survival (OS) was 47.7% and 20.2% in the IACA low- and intermediate-risk groups, respectively, which were both significantly higher than that of the high-risk group (0.0%). In the IACA low-risk groups, the 2-year probability of OS in patients receiving IC was significantly higher than in those receiving best supportive care (50.8% vs. 0.0%, P<0.001) .
Conclusion
We observed that the IACA index could predict the clinical outcomes of elderly patients with AML, and the IACA low-risk patients may benefit more from IC.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, Elderly
Abstract: PB1722
Type: Publication Only
Background
Acute myeloid leukemia (AML) is one of the common types of hematological malignancies in elderly people. Thus, how to select patients who are suitable to receive intensive induction chemotherapy is critical to improve the clinical outcomes of elderly patients with AML. Over the last few decades, geriatricians have developed comprehensive geriatric assessment (CGA) methods for elderly patients, which are useful for the evaluation of cancer patients. however, the tools used for CGA varied and not uniform in AML.
Aims
We aimed to validate the instrumental activities of daily living (IADL) scales, age, comorbidities, and albumin (IACA) index in elderly patients with acute myeloid leukemia (AML) and identify whether this index can serve as a guide for optimal personalized therapy for elderly patients with AML.
Methods
Patients aged ≥60 years, who had been diagnosed with AML in the Department of Hematology, Beijing Hospital, were screened for eligibility (n = 61).
Results
A total of 21, 34, and 6 patients were categorized as IACA low-risk, intermediate-risk, and high-risk groups, respectively. Thirty-nine patients received induction chemotherapy (IC, n=35) or decitabine (n=4) after diagnosis, 19 (48.7%) achieved complete remission (CR), and the rate of CR was significantly higher in the IACA low-risk group than that of intermediate-risk group (68.4% vs. 30.0%, P=0.016).The rates of grade ≥ 3 toxicities and treatment-related mortality were comparable between low- and intermediate-risk groups. The rate of relapse/progression-related mortality was 23.8%, 58.8%, and 100.0% in the IACA low-, intermediate-, and high-risk groups, respectively (P<0.001). The 2-year probability of overall survival (OS) was 47.7% and 20.2% in the IACA low- and intermediate-risk groups, respectively, which were both significantly higher than that of the high-risk group (0.0%). In the IACA low-risk groups, the 2-year probability of OS in patients receiving IC was significantly higher than in those receiving best supportive care (50.8% vs. 0.0%, P<0.001) .
Conclusion
We observed that the IACA index could predict the clinical outcomes of elderly patients with AML, and the IACA low-risk patients may benefit more from IC.
Session topic: 4. Acute myeloid leukemia - Clinical
Keyword(s): Acute Myeloid Leukemia, Elderly